• SmD2 Acetylation Links Splicing to PARP Sensitivity

  2026-09-10

  This 2024 Nature Communications study identifies SmD2 acetylation as a regulatory link between core spliceosome function, BRCA1/FANC cassette-exon usage, DNA-damage responses, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its findings support investigating HDAC2-directed epigenetic modulation, including Romidepsin plus olaparib, as a strategy for exposing a therapeutically actionable vulnerability in HCC models.

• Rimonabant (SR141716) in CB1 Research

  2026-09-10

  Rimonabant (SR141716) provides a selective CB1 blockade strategy for separating endocannabinoid signaling from appetite, inflammatory, and pain-related phenotypes. This workflow-focused guide shows how to prepare, deploy, and troubleshoot the compound while using the latest terpene pain research to sharpen mechanism-of-action controls.

• Albiflorin Inhibits RCC via EGFR/MAPK Signaling

  2026-09-09

  This study combines cell-based assays, network pharmacology, molecular docking, and pathway rescue experiments to show that albiflorin suppresses renal cell carcinoma proliferation and migration. Its findings prioritize EGFR/MAPK signaling and MMP9/FGF2 regulation as testable mechanisms, while also defining important limits for translation beyond cultured cells.

• Rocket-Like Nanomedicine Restores PDAC Stromal Homeostasis

  2026-09-09

  The reference study develops an acid-responsive, multistage nanomedicine that combines stromal remodeling with gemcitabine delivery for pancreatic ductal adenocarcinoma. Its central innovation is sequential release of halofuginone and IPR-803 to reduce stromal resistance and improve intratumoral access to gemcitabine, producing marked tumor regression in a pancreatic cancer mouse model.

• Paclitaxel (Taxol) in Cancer Research Workflows

  2026-09-09

  Build reproducible cancer research assays around Paclitaxel (Taxol), from DMSO stock preparation and dose finding to cell-cycle and microtubule readouts. This workflow also uses Paclitaxel as a mechanistically distinct comparator when studying IL-6/GP130 signaling and bazedoxifene response.

• Cefoperazone Sodium Salt: Assay Workflows

  2026-09-08

  Build reproducible MIC, MBC, and β-lactamase-resistance experiments with Cefoperazone sodium salt. This guide connects practical stock preparation and microdilution design with comparative evidence and carefully bounded biliary tract infection research.

• Metabolomics of Carbapenemase-Producing Enterobacterales

  2026-09-07

  A 2025 study used LC-MS/MS metabolomics and supervised machine learning to distinguish carbapenemase-producing from non-producing Enterobacterales in antibiotic-free cultures. Its biomarker panel links resistance phenotypes with altered metabolic pathways and suggests a route toward faster resistance detection, while still requiring external validation.

• Metformin HCl Beyond Glucose: AMPK and Fibrosis

  2026-09-07

  Metformin Hydrochloride is increasingly valuable as a mechanistic research tool beyond glucose biology. Evidence from a rabbit vocal fold injury model and fibroblast experiments connects AMPK activation with reduced fibrotic remodeling, while highlighting the controls and translational boundaries researchers should address.

• JZL184: Selective Monoacylglycerol Lipase Inhibitor

  2026-09-05

  JZL184 is a selective monoacylglycerol lipase inhibitor that increases 2-arachidonoylglycerol availability and enables controlled endocannabinoid signaling modulation. It is a research tool for CB1 receptor mediated synaptic modulation, analgesia and antinociception research, and anxiolytic effects in rodent models.

• PPM-18: Designing Causal iNOS Assays

  2026-09-04

  PPM-18 is an NF-κB-linked inhibitor of inducible nitric oxide synthase expression for dissecting inflammatory signaling. This article presents a causal, multi-readout assay strategy that connects macrophage signaling, nitric oxide biology, and carefully bounded applications in bone research.

• Triple Inhibition in BRAFV600E Melanoma

  2026-09-04

  A 2026 study shows that eIF4F inhibition can trigger adaptive ERK1/2–EZH2 and AKT1–eIF4E signaling in BRAFV600E melanoma cells. Combining eIF4F, EZH2, and AKT1 inhibitors improved apoptosis and reduced resistance to both RocA and vemurafenib in cell and animal models.

• Anagliptin Beyond Glycemic Control

  2026-09-03

  An evidence-led perspective on Anagliptin (SK-0403) as both a DPP-4 research tool and a probe of vascular smooth-muscle physiology, with practical guidance for validating Kv channel and SERCA pump involvement.

• BIRB 796: Allosteric Precision in Translational Research

  2026-09-03

  BIRB 796, or Doramapimod, illustrates how allosteric p38α MAPK inhibition can connect target selectivity, phosphatase-aware mechanism, and translational decision-making across inflammation, apoptosis, and cancer research.

• Syringin: Designing Mechanism-Ready Assays

  2026-09-02

  Syringin natural product research is strongest when chemical identity, combination pharmacology, phenotype, and pathway evidence are integrated. This guide converts RCC findings into a reproducible assay strategy while highlighting practical limitations and interpretation safeguards.

• MEHP, AhR, and Ovarian Follicle Toxicity

  2026-09-02

  Neff and colleagues show that mono(2-ethylhexyl) phthalate disrupts mouse ovarian follicle growth and estrogen-related signaling partly through aryl hydrocarbon receptor activation. Pharmacological blockade with CH 223191 reduced several MEHP-associated effects, positioning AhR signaling as a mechanistic link between phthalate exposure, altered steroidogenesis, and reproductive toxicity.

8422 records 1/562 page Next 12345 下5页 Last page